Company profile

Freenome Health

Freenome Health has raised $1.35 billion to date, including a $290 million Series D led by Roche and a $254 million Series E in February 2024 led by T. Rowe Price and Fidelity Investments. Founded in 2014, the U.S.-based company develops AI-driven blood tests for early cancer detection, using deep learning to analyze cell-free DNA and metabolic markers. With over 530 employees and partnerships across the healthcare ecosystem, Freenome is advancing toward FDA approval and large-scale commercialization of its colorectal cancer screening test.

Back to profiles

Quick facts

Total funding: $1.35 billion
Founded: 2014
Employees: 530

Notable investors

Roche

Reach buyers like Freenome Health on TexAu

TexAu helps go-to-market teams find, enrich, and reach companies that match this profile. Pick the path that fits how you work.

Find companies like Freenome Health
Build a list by industry, headcount, funding stage, or technographics. Get verified emails and direct dials.
Start a free workspace
Enrich your CRM with company data
Push funding, headcount, hiring signals, and tech stack into HubSpot, Salesforce, or a spreadsheet. Waterfall enrichment.
See how the waterfall works
Run it on a schedule
Refresh the list weekly, score new accounts as they land, and push the ones that fit to Smartlead, Instantly, Lemlist, HeyReach, or Apollo Sequences.
See how schedulers work

Reach buyers like Freenome Health.

The 14-day trial ships every feature, no card required.

Start free →